masoprocol and Precancerous Conditions

masoprocol has been researched along with Precancerous Conditions in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (66.67)	18.2507
2000's	1 (33.33)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Ashfaq, R; Bernstein, HS; Brock, M; Deasel, M; Dhara, S; Forastiere, A; Hansel, DE; Harmon, J; Huang, RC; Maitra, A; Montgomery, E; Shimada, Y; Washington, MK	1
Denda, A; Endoh, T; Horiguchi, K; Kobayashi, E; Konishi, Y; Nakae, D; Noguchi, O; Ogasawara, H; Sugimura, M; Tamura, K; Tang, Q; Tsujiuchi, T	1
Barnaby, JW; Cockerell, CJ; Styles, AR	1

Reviews

1 review(s) available for masoprocol and Precancerous Conditions

Article	Year
Actinic keratoses. Differential diagnosis and treatment. Drugs & aging, 1997, Volume: 11, Issue:3 Topics: Aging; Chemexfoliation; Combined Modality Therapy; Cryosurgery; Curettage; Dermabrasion; Diagnosis, Differential; Electrosurgery; Fluorouracil; Humans; Keratolytic Agents; Keratosis; Laser Therapy; Masoprocol; Precancerous Conditions	1997

Other Studies

2 other study(ies) available for masoprocol and Precancerous Conditions

Article	Year
CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target. The American journal of surgical pathology, 2005, Volume: 29, Issue:3 Topics: Adenocarcinoma; Barrett Esophagus; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagus; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Masoprocol; Precancerous Conditions; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis	2005
Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats. Carcinogenesis, 1996, Volume: 17, Issue:3 Topics: Acetophenones; Animals; Aspirin; Choline; Choline Deficiency; Cyclooxygenase Inhibitors; Fatty Liver; gamma-Glutamyltransferase; Glutathione Transferase; Lipoxygenase Inhibitors; Liver; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Male; Masoprocol; Methionine; Oxidative Stress; Phospholipases A; Phospholipases A2; Precancerous Conditions; Quercetin; Rats; Rats, Inbred F344; Time Factors	1996

Article

Year

CDC2/CDK1 expression in esophageal adenocarcinoma and precursor lesions serves as a diagnostic and cancer progression marker and potential novel drug target.

The American journal of surgical pathology, 2005, Volume: 29, Issue:3

Topics: Adenocarcinoma; Barrett Esophagus; CDC2 Protein Kinase; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Disease Progression; Dose-Response Relationship, Drug; Esophageal Neoplasms; Esophagus; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Masoprocol; Precancerous Conditions; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis

2005

Inhibition by acetylsalicylic acid, a cyclo-oxygenase inhibitor, and p-bromophenacylbromide, a phospholipase A2 inhibitor, of both cirrhosis and enzyme-altered nodules caused by a choline-deficient, L-amino acid-defined diet in rats.

Carcinogenesis, 1996, Volume: 17, Issue:3

Topics: Acetophenones; Animals; Aspirin; Choline; Choline Deficiency; Cyclooxygenase Inhibitors; Fatty Liver; gamma-Glutamyltransferase; Glutathione Transferase; Lipoxygenase Inhibitors; Liver; Liver Cirrhosis, Experimental; Liver Neoplasms, Experimental; Male; Masoprocol; Methionine; Oxidative Stress; Phospholipases A; Phospholipases A2; Precancerous Conditions; Quercetin; Rats; Rats, Inbred F344; Time Factors

1996